title: Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver--magnetic nanoparticles in cancer treatment.
abstract: BACKGROUND
  Magnetic drug targeting is a new treatment principle for tumors using cytostatics coupled to ferromagnetic nanoparticles and extracorporeal magnets. Higher concentrations in tumor tissue with lower systemic concentrations and without damage of healthy organs should be achieved.
  
  
  METHODS
  n = 42 adult Wag/Rij rats were transfected with rhabdomyosarcoma R(1)H in their right gastrocnemius muscle. In the biodistribution trial (n = 36) concentrations of mitoxantrone-iron oxide with and without an extracorporeal 0.6 tesla magnet and regular mitoxantrone were measured in plasma and tumor tissue for one- and two-dose administration. In the plasma iron trial (n = 6) iron concentrations were measured in plasma before, during, and up to 30 min after drug administration. Seven days after the trial liver, spleen and tumor samples were obtained and histologically assessed.
  
  
  RESULTS
  Mitoxantrone iron-oxide concentration in plasma was significantly (P < 0.05) lower when a magnet was placed over the tumor area and as low as uncoupled mitoxantrone. Mitoxantrone concentration in tumor tissue was always significantly higher with magnetic drug targeting when compared with uncoupled mitoxantrone. Two doses resulted in drug accumulation in tumor tissue. Plasma iron concentrations rose when the drug was first administered. Plasma levels fell below the starting level with a magnet applied. A rebound phenomenon with rising iron concentrations was observed after the magnet was removed. Tumors showed fresh necrosis and liver and spleen had detectable iron depositions but no necrosis 7 d after treatment. No allergies or toxic reactions were observed.
  
  
  CONCLUSIONS
  We showed that magnetic drug targeting achieves higher concentrations of cytostatics in tumor tissue compared with blood. During magnetic drug targeting, iron particles are quickly sliced and kept in the tumor area. Organs of the reticuloendothelial system are not affected by cytostatic damage.
authors.affiliation: Department of Radio-Oncology, Radiation Hospital, Paracelsus Hospitals, Osnabrück, Germany. dr-krukemeyer@t-online.de
authors.forename: Manfred G
authors.initials: MG
authors.lastname: Krukemeyer
authors.forename: Veit
authors.initials: V
authors.lastname: Krenn
authors.forename: Martin
authors.initials: M
authors.lastname: Jakobs
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Wagner
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D005290:Ferric Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008099:Liver / Q000503:physiopathology; D058185:Magnetite Nanoparticles; D008942:Mitoxantrone / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010949:Plasma / Q000502:physiology; D051381:Rats; D012208:Rhabdomyosarcoma / Q000188:drug therapy* / Q000503:physiopathology; D013154:Spleen / Q000503:physiopathology
chemical_list: D000970:Antineoplastic Agents; D005290:Ferric Compounds; D058185:Magnetite Nanoparticles; C000499:ferric oxide; D008942:Mitoxantrone